Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 5/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | POLA1 | P09884 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3034063 | 1.00 | LMNA (1.00) | LMNAALDH1A1MAPTABCC4TSHR | |
| SCHEMBL346766 | 1.00 | LMNA (1.00) | LMNAALDH1A1MAPTABCC4TSHR | |
| SCHEMBL11326603 | 1.00 | LMNA (1.00) | LMNAALDH1A1MAPTABCC4TSHR | |
| SCHEMBL21352704 | 1.00 | LMNA (1.00) | LMNAALDH1A1MAPTABCC4TSHR | |
| SCHEMBL21352709 | 1.00 | LMNA (1.00) | LMNAALDH1A1MAPTABCC4TSHR | |
| SCHEMBL515291 | 1.00 | LMNA (1.00) | LMNAALDH1A1MAPTABCC4TSHR | |
| SCHEMBL9244114 | 1.00 | LMNA (1.00) | LMNAALDH1A1MAPTABCC4TSHR | |
| SCHEMBL9329621 | 1.00 | LMNA (1.00) | LMNAALDH1A1MAPTABCC4TSHR | |
| SCHEMBL196188 | 1.00 | LMNA (1.00) | LMNAALDH1A1MAPTABCC4TSHR | |
| SCHEMBL490162 | 1.00 | LMNA (1.00) | LMNAALDH1A1MAPTABCC4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080086-A | Diimine catalyst, preparation method and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| US-20240269320-A1 | EXTENDED RELEASE DRUG DELIVERY SYSTEM FOR OCULAR DRUGS AND METHODS OF USE | EYEDEA BIO, LLC | 2024-08-15 | — | — | US | claimed |
| US-20240269292-A1 | INTRAVITREAL MITOCHONDRIAL-TARGETED PEPTIDE PRODRUGS AND METHODS OF USE | EYEDEA BIO, LLC | 2024-08-15 | — | — | US | claimed |
| EP-4351612-A2 | EXTENDED RELEASE DRUG DELIVERY SYSTEM FOR OCULAR DRUGS AND METHODS OF USE | Eyedea Bio, Llc (US) | 2024-04-17 | — | — | EP | claimed |
| CN-117881411-A | Extended release drug delivery system for ocular drugs and methods of use | 艾迪雅生物有限责任公司 | 2024-04-12 | — | — | CN | claimed |
| EP-4347616-A2 | INTRAVITREAL MITOCHONDRIAL-TARGETED PEPTIDE PRODRUGS AND METHODS OF USE | Eyedea Bio, Llc (US) | 2024-04-10 | — | — | EP | claimed |
| CN-117858888-A | Intravitreal mitochondrial targeting peptide prodrugs and methods of use thereof | 艾迪雅生物有限责任公司 | 2024-04-09 | — | — | CN | claimed |
| EP-2970533-B1 | LUBRICANT COMPOSITIONS INCLUDING ALPHA-OLEFIN COPOLYMERS | WILMAR TRADING PTE LTD (SG) | 2023-07-19 | — | — | EP | claimed |
| WO-2022256412-A2 | EXTENDED RELEASE DRUG DELIVERY SYSTEM FOR OCULAR DRUGS AND METHODS OF USE | EYEDEA BIO, LLC (US) | 2022-12-08 | — | — | WO | claimed |
| WO-2022256377-A2 | INTRAVITREAL MITOCHONDRIAL-TARGETED PEPTIDE PRODRUGS AND METHODS OF USE | EYEDEA BIO, LLC (US) | 2022-12-08 | — | — | WO | claimed |
| CN-105143287-A | Lubricant compositions comprising alpha-olefin copolymers | ELEVANCE RENEWABLE SCIENCES | 2015-12-09 | — | — | CN | claimed |
| WO-2014159326-A2 | LUBRICANT COMPOSITIONS INCLUDING ALPHA-OLEFIN COPOLYMERS | ELEVANCE RENEWABLE SCIENCES, INC. (US) | 2014-10-02 | — | — | WO | claimed |
| US-20140274843-A1 | LUBRICANT COMPOSITIONS INCLUDING ALPHA-OLEFIN COPOLYMERS | ELEVANCE RENEWABLE SCIENCES, INC. (US) | 2014-09-18 | — | — | US | claimed |
| US-7479531-B2 | Copolymer of ethylene and/or propylene; and octen-1-ol,7-octen-1-ol trimethylsilyl ether, octenyl acetate, 5-norbornen-2-yl acetate, 5-norbornen-2-ol and/or 5-norbornen-2-ol trimethylsilyl ether; transition metal catalyst comprising 2-arylazo- or 2-arylphosphazo- phenoxide ligand | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2009-01-20 | — | — | US | claimed |
| US-7285609-B2 | Olefin polymerization catalyst system useful for polar monomers | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-10-23 | — | — | US | claimed |
| EP-1626999-B1 | OLEFIN POLYMERIZATION CATALYST SYSTEM USEFUL FOR POLAR MONOMERS | EXXONMOBIL CHEM PATENTS INC (US) | 2007-09-26 | — | — | EP | claimed |
| US-20070197751-A1 | Olefin polymerization catalyst system useful for polar monomers | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-08-23 | — | — | US | claimed |
| EP-1626999-A1 | OLEFIN POLYMERIZATION CATALYST SYSTEM USEFUL FOR POLAR MONOMERS | Exxonmobil Chemical Patents Inc. (US) | 2006-02-22 | — | — | EP | claimed |
| US-20040260043-A1 | Olefin polymerization catalyst system useful for polar monomers | EXXONMOBIL CHEMICAL PATENTS, INC. | 2004-12-23 | — | — | US | claimed |
| WO-2004101634-A1 | OLEFIN POLYMERIZATION CATALYST SYSTEM USEFUL FOR POLAR MONOMERS | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2004-11-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269292-A1 | INTRAVITREAL MITOCHONDRIAL-TARGETED PEPTIDE PRODRUGS AND METHODS OF USE | PDF, PITRM1, ATP5PD | LMNA 1398/4885ALDH1A1 1949/4885MAPT 561/4885 |
| US-20240269320-A1 | EXTENDED RELEASE DRUG DELIVERY SYSTEM FOR OCULAR DRUGS AND METHODS OF USE | CHMP4B, UACA, VEGFA | LMNA 2983/4885ALDH1A1 1229/4885MAPT 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.